Antibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices? (Q40891394)

24 September 2017

title

Antibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices? (English)

1 reference

24 September 2017

Schmitz FJ

1

1 reference

24 September 2017

Jones ME

series ordinal

2

1 reference

24 September 2017

publication date

1 June 1997

1 reference

International Journal of Antimicrobial Agents

24 September 2017

published in

1 reference

24 September 2017

volume

9

1 reference

24 September 2017

issue

1

1 reference

24 September 2017

page(s)

1-19

1 reference

Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The worldwide prevalence of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant Staphylococcus aureus in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The evolving epidemiology of methicillin-resistant Staphylococcus aureus at a university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant Staphylococcus aureus (MRSA): a briefing for acute care hospitals and nursing facilities. The AHA Technical Panel on Infections Within Hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Antimicrobial-resistant pathogens in the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Origin and evolution of DNA associated with resistance to methicillin in staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

New mechanism for methicillin resistance in Staphylococcus aureus: clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Borderline susceptibility to antistaphylococcal penicillins is not conferred exclusively by the hyperproduction of beta-lactamase

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Vancomycin therapy for methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant staphylococci: detection methods and treatment of infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Mode of action and in-vitro activity of vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Treatment of infections due to methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Staphylococcus aureus and vancomycin: the sequel

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Structure, biochemistry and mechanism of action of glycopeptide antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The role of Gram-positive therapy in the neutropenic patient

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Towards the ideal glycopeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The antimicrobial activity of fusidic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Vancomycin in infants and children: a review of pharmacology and indications for therapy and prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

A prospective study of adverse reactions associated with vancomycin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Lipohypertrophy and glomerulonephritis after the use of aprotinin in an insulin-dependent diabetic.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The "red man's syndrome" and slow infusion of vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Influence of antihistamine pretreatment on vancomycin-induced red-man syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Vancomycin Therapy in Patients with Impaired Renal Function: A Nomogram for Dosage

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Persistence of Vancomycin in the Blood during Renal Failure and Its Treatment by Hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Staphylococcal sepsis in patients on chronic hemodialysis regimens: intravenous treatment with vancomycin given once weekly

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Topical vancomycin for the treatment of Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus conjunctivitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Instillation of vancomycin into a cerebrospinal fluid reservoir to clear infection: pharmacokinetic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

A risk-benefit assessment of teicoplanin in the treatment of infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Microbiological properties of teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Dosage recommendations for teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Clinical evaluation of teicoplanin in the treatment of gram-positive bacterial intravascular infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

A review of the safety profile of teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Teicoplanin in endocarditis: a multicentre, open European study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Protection against gentamicin nephrotoxicity by daptomycin in nephrectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro activity of the semisynthetic glycopeptide amide MDL 63,246

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Structure-activity relationships of vancomycin-type glycopeptide antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparative activity of CGP 31608, nafcillin, cefamandole, imipenem, and vancomycin against methicillin-susceptible and methicillin-resistant staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Imipenem therapy of experimental Staphylococcus epidermidis endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Clinical, epidemiologic and bacteriologic observations of an outbreak of methicillin-resistant Staphylococcus aureus at a large community hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Efficacy of prophylaxis with beta-lactams and beta-lactam-beta-lactamase inhibitor combinations against wound infection by methicillin-resistant and borderline-susceptible Staphylococcus aureus in a guinea pig model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Beta-Lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Emergence of resistance to cephalothin and gentamicin during combination therapy for methicillin-resistant Staphylococcus aureus endocarditis in rabbits.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Efficacy of ticarcillin-clavulanic acid for treatment of experimental Staphylococcus aureus endocarditis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental endocarditis due to Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Excellent activity of FK037, a novel parenteral broad-spectrum cephalosporin, against methicillin-resistant staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Antibacterial properties of SCE-2787, a new cephem antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with a broad antibacterial spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Discovery and structure-activity relationship of a series of 1-carba-1-dethiacephems exhibiting activity against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo antibacterial activities of BO-2727, a new carbapenem

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Epidemiological study of Staphylococcus aureus resistance to new quinolones in a university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Molecular epidemiology and antimicrobial susceptibility testing. Testing of quinolone-resistant Staphylococcus aureus strains isolated in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Epidemiology of ciprofloxacin resistance among patients with methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Oxacillin- and quinolone-resistant Staphylococcus aureus in Sao Paulo, Brazil: a multicenter molecular epidemiology study.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. An in vitro look at alternative antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro activity of various antimicrobial agents against Staphylococcus aureus isolates including fluoroquinolone- and oxacillin-resistant strains

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Oral temafloxacin versus vancomycin for therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Fluoroquinolone resistance an evolving national problem or just a problem for some physicians?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

New quinolones and gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Antimicrobial activity of DV-7751a, a new fluoroquinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Trimethoprim-sulphamethoxazole treatment in staphylococcal endocarditis and gram-negative septicemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo efficacy of the combination trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Trimethoprim-sulfamethoxazole treatment of multiantibiotic-resistant staphylococcal endocarditis and meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Emergence of gentamicin- and methicillin-resistant Staphylococcus aureus strains in New York City hospitals.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Levels of rifampin and ciprofloxacin in nasal secretions: correlation with MIC90 and eradication of nasopharyngeal carriage of bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Clinical Study of Combination Therapy with Oxacillin and Rifampin for Staphylococcal Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The Efficacy of Rifampin as Adjunctive Therapy in Selected Cases of Staphylococcal Endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Efficacy of short courses of oral novobiocin-rifampin in eradicating carrier state of methicillin-resistant Staphylococcus aureus and in vitro killing studies of clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Rifampin resistance. Development during the therapy of methicillin-resistant Staphylococcus aureus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro activity of minocycline and rifampin against staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Antistaphylococcal Activity of Rifampin with Other Antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Clindamycin for colonization and infection by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Activity of clindamycin against Staphylococcus aureus and Staphylococcus epidermidis from four UK centres

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

1 reference

7 January 2021

Letter: Syntheses of 1-n-(S)-4-amino-2-hydroxybutyryl)-kanamycin B and -3', 4'-dideoxykanamycin B active against kanamycin-resistant bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Antimicrobial chemotherapy of septicemia due to methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Adverse reactions to intravenous administration of fusidic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Fucidin for staphylococcal infection of burns

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

A fatal infection caused by methicillin-resistant Staphylococcus aureus acquiring resistance to gentamicin and fusidic acid during therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Failure of a combination of vancomycin and fusidic acid in a patient with staphylococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

A multicentre, open, clinical trial of a new intravenous formulation of fusidic acid in severe staphylococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Susceptibility of methicillin-resistant Staphylococcus aureus to minocycline and other antimicrobials.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Minocycline as an alternative antistaphylococcal agent

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Synergistic interaction of antibiotics with nasal penetration to methicillin-sensitive and methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro and in vivo study of fosfomycin in methicillin-resistant Staphylococcus aureus septicaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Recent developments in the field of phosphonic acid antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

RP 59500: a proposed mechanism for its bactericidal activity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The molecular basis of the inhibitory activities of type A and type B synergimycins and related antibiotics on ribosomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparative in-vitro activity of RP 59500 against clinical bacterial isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Evolution and present situation of Staphylococcus aureus sensitivity to MLS in hospital (1975-83).

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The carrier state: methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Epidemiologic studies of an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

An Outbreak of Infections Caused by Strains of Staphylococcus aureus Resistant to Methicillin and Aminoglycosides. II. Epidemiologic Studies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant Staphylococcus aureus: microbiologic characteristics, antimicrobial susceptibilities, and assessment of virulence of an epidemic strain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

SOME ASPECTS OF NASAL CARRIAGE OF STAPHYLOCOCCI

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

PERSON-TO-PERSON TRANSMISSION OF STAPHYLOCOCCUS AUREUS. QUANTITATIVE CHARACTERIZATION OF NASAL CARRIERS SPREADING INFECTION

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant Staphylococcus aureus nasal carriage and infections in CAPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant staphylococcal colonization and infection in a long-term care facility.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

A comparison of clinical virulence of nosocomially acquired methicillin-resistant and methicillin-sensitive Staphylococcus aureus infections in a university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The effect of methicillin on skin lesions in guinea-pigs caused by "methicillin-sensitive" and "methicillin-resistant" Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Nasal carriage of Staphylococcus aureus and cross-contamination in a surgical intensive care unit: efficacy of mupirocin ointment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Prospective study of infection, colonization and carriage of methicillin-resistant Staphylococcus aureus in an outbreak affecting 990 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Effectiveness of simple measures to control an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections in an intensive care unit.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Control of epidemic methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The value of nasal mupirocin in containing an outbreak of methicillin-resistant Staphylococcus aureus in an orthopaedic unit

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-Resistant Staphylococcus aureus in Hospitals and Long-Term Care Facilities: Microbiology, Epidemiology, and Preventive Measures

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Mupirocin ('pseudomonic acid')--a promising new topical antimicrobial agent

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Minimal dose requirements for nasal mupirocin and its role in the control of epidemic MRSA.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Eradication of colonization by methicillin-resistant Staphylococcus aureus by using oral minocycline-rifampin and topical mupirocin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

An outbreak of infection with a methicillin-resistant Staphylococcus aureus in a special care baby unit: value of topical mupirocin and of traditional methods of infection control

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Nasal carriage of Staphylococcus aureus treated with topical mupirocin (pseudomonic acid) in a children's hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Elimination of nasal carriage of methicillin-resistant Staphylococcus aureus with mupirocin during a hospital outbreak.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Mupirocin resistance among consecutive isolates of oxacillin-resistant and borderline oxacillin-resistant Staphylococcus aureus at a university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparison of the in-vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Topical antibiotic ointments for staphylococcal nasal carriers: survey of current practices and comparison of bacitracin and vancomycin ointments

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Interaction of pseudomonic acid A with Escherichia coli B isoleucyl-tRNA synthetase

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Biochemical basis of mupirocin resistance in strains of Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Mechanism of mupirocin transport into sensitive and resistant bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Diversity of staphylococci exhibiting high-level resistance to mupirocin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

The antimicrobial activity of mupirocin—an update on resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Sensitivity to mupirocin of staphylococci isolated from colonized or infected patients in Germany

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

Methicillin-resistant Staphylococcus aureus in a London hospital.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2897%2900027-7

7 January 2021

10.1016/S0924-8579(97)00027-7

Identifiers

DOI

1 reference

24 September 2017

1 reference